683 Capital Management »

Rani Therapeutics Hldgs shares owned by 683 Capital Management

Quarter-by-quarter ownership of Rani Therapeutics Hldgs (RANI) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Rani Therapeutics Hldgs

Tip: Access up to 7 years of quarterly data

All positions including Rani Therapeutics Hldgs held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rani Therapeutics Hldgs by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $658k 487k 1.35

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. Put Option (LLY)
Capital One Financial (COF)
Tesla Motors Put Option (TSLA)
NVIDIA Corporation Put Option (NVDA)
Wave Life Sciences SHS (WVE)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Alnylam Pharmaceuticals (ALNY)
Praxis Precision Medicines I Com New Put Option (PRAX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Protagonist Therapeutics (PTGX)
Gxo Logistics Incorporated Common Stock (GXO)
Hilton Grand Vacations (HGV)
Anaptysbio Inc Common (ANAB)

View all positions for 683 Capital Management

Top funds holding Rani Therapeutics Hldgs

Samsara BioCapital
AWM Investment Company
Vanguard Group
Susquehanna International
Jane Street
Geode Capital Management
Nan Fung Group Holdings
683 Capital Management
Citadel Advisors
State Street Corporation
Squarepoint Ops
United Services Automobile Association
Goldman Sachs Group
Kestra Private Wealth Services
Takeda Pharmaceutical

View all funds holding Rani Therapeutics Hldgs